Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, ECO, WOM

The Institute for Women's Policy Research (IWPR) Announces Major New Grant from Melinda French Gates for Its Economic Equity and Women's Health Research


The Institute for Women's Policy Research (IWPR) today announced the receipt of a new substantial grant from philanthropist Melinda French Gates, founder of Pivotal.

WASHINGTON, May 28, 2024 The Institute for Women's Policy Research (IWPR) Announces Major New Grant from Melinda French Gates for Its Economic Equity and Women's Health Research

"I am deeply grateful to Ms. French Gates for her continued leadership on behalf of women everywhere and for the confidence she has shown in IWPR with this support," said Dr. Jamila K. Taylor, IWPR President and CEO.

The Institute for Women's Policy Research (IWPR) today announced the receipt of a new substantial grant from philanthropist Melinda French Gates, founder of Pivotal. The grant is part of a significant new funding commitment from Ms. French Gates to promote women's empowerment globally in light of the recent setbacks in women's rights and growing challenges to social progress in the U.S. and worldwide.

"We are deeply honored to receive this support from Melinda French Gates, a true pioneer for women's empowerment," said Dr. Jamila K. Taylor, IWPR President and CEO. "This grant will play a key role in advancing our work to win economic equity for all women and improve women's health across the United States. I am deeply grateful to Ms. French Gates for her continued leadership on behalf of women everywhere and for the confidence she has shown in IWPR with this support."

Today, May 28, Melinda French Gates kicked off the next chapter of her philanthropic efforts by dedicating significant new funding to promote women's empowerment globally. In doing so, she emphasized the urgent need to infuse capital into organizations and individuals committed to advancing equality and dismantling barriers impeding women's progress.

"My commitment is to ensure we are doing more to unlock women and girls' power, and we are accelerating progress now," said Melinda French Gates, founder of Pivotal. "The organizations we're working with have a proven track record in fighting to protect women's rights and advancing their power and influence in the United States. I look forward to all they will continue to accomplish."

The Institute for Women's Policy Research strives to win economic equity for all women and eliminate barriers to their full participation in society. As a leading national think tank, IWPR builds evidence to shape policies that grow women's power and influence, close inequality gaps, and improve the economic well-being of families. Learn more at http://www.iwpr.org.

Media Contact

William Lutz, IWPR, 2027855100, [email protected], iwpr.org

SOURCE IWPR


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: